NF-κB-Mediated Neuroinflammation in Parkinson's Disease and Potential Therapeutic Effect of Polyphenols

Neurotox Res. 2020 Mar;37(3):491-507. doi: 10.1007/s12640-019-00147-2. Epub 2019 Dec 10.

Abstract

Different animal and human studies from last two decades in the case of Parkinson's disease (PD) have concentrated on oxidative stress due to increased inflammation and cytokine-dependent neurotoxicity leading to induction of dopaminergic (DA) degeneration pathway in the nigrostriatal region. Chronic inflammation, the principle hallmark of PD, forms the basis of neurodegeneration. Aging in association with activation of glia due to neuronal injury, perhaps because of immune alterations and genetic predispositions, leads to deregulation of inflammatory pathways premising the onset of PD. A family of inducible transcription factors, nuclear factor-κB (NF-κB), is found to show expression in various cells and tissues, such as microglia, neurons, and astrocytes which play an important role in activation and regulation of inflammatory intermediates during inflammation. Both canonical and non-canonical NF-κB pathways are involved in the regulation of the stimulated cells. During the prodromal/asymptomatic stage of age-associated neurodegenerative diseases (i.e., PD and AD), chronic neuroinflammation may act silently as the driver of neuronal dysfunction. Though research has provided an insight over age-related neurodegeneration in PD, elaborative role of NF-κB in neuroinflammation is yet to be completely understood and thus requires more investigation. Polyphenols, a group of naturally occurring compound in medicinal plants, have gained attention because of their anti-oxidative and anti-neuroinflammatory properties in neurodegenerative diseases. In this aspect, this review highlights the role of NF-κB and the possible therapeutic roles of polyphenols in NF-κB-mediated neuroinflammation in PD.

Keywords: Astrocytes; Microglia; NF-κB; Neuroinflammation; Oxidative stress; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / administration & dosage*
  • Brain / drug effects
  • Brain / metabolism*
  • Encephalitis / etiology
  • Encephalitis / metabolism*
  • Humans
  • NF-kappa B / metabolism*
  • Neurons / drug effects
  • Neurons / metabolism
  • Parkinson Disease / etiology
  • Parkinson Disease / metabolism*
  • Parkinson Disease / prevention & control*
  • Polyphenols / administration & dosage*
  • Reactive Oxygen Species

Substances

  • Antiparkinson Agents
  • NF-kappa B
  • Polyphenols
  • Reactive Oxygen Species